React4life Updates

We are proud to be cited in an article by the UK Federation of Small Businesses (FSB) titled “The Hidden Reality of Laboratory Testing in the UK.
The piece explores innovation and challenges in preclinical testing and highlights React4life’s contribution to advancing organ-on-chip technologies as a human-relevant alternative to animal models.

The MIVO-HTS project aims to develop a scalable organ-on-chip platform for high-throughput immuno-oncology studies. It integrates circulating human immune cells with 3D tumor models, offering predictive preclinical results while reducing animal testing.

React4Life has been selected to join the BioTools Innovator 2024 Accelerator, a prestigious four-month accelerator connecting top life science startups with mentors, investors, and industry experts. The program will help advance the company’s organ-on-chip platforms for predictive preclinical research.

React4Life participates in the BIO International Convention 2024 in San Diego.
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech.

MIVO® technology revolutionizes skin absorption testing by accurately replicating physiological microcirculation, improving predictions for both hydrophilic and lipophilic compounds. A recent collaboration between React4Life and Merck led to a landmark study showcasing MIVO®’s potential to bridge in vitro assays and in vivo relevance, supporting regulatory compliance and faster development of safer, more effective products.

This work explores a pioneering approach to oral drug bioavailability assessment developed through a collaboration with the University of Oslo. By integrating dissolution and permeation within the MIVO® platform, they demonstrate how physiologically relevant, modular in vitro systems can transform formulation development and accelerate translational decision-making.

PRESSURE, a Horizon Europe Marie Skłodowska-Curie Actions Doctoral Network, unites leading European experts to tackle therapy resistance in esophageal adenocarcinoma (EAC). By integrating omics data, patient response profiles, and advanced EAC models, PRESSURE aims to develop optimized treatments and train a new generation of researchers to revolutionize cancer therapy.

Combining 3D cell cultures with dynamic perfusion, MIVO® provides a human-relevant platform for investigating drug efficacy, toxicity, and immune responses.
It simulates human tissue interactions, enabling more accurate drug testing and mechanistic studies while reducing reliance on animal models.

Recognized among the 100 Italian Excellences, React4life stands out for its continuous contribution to scientific innovation and commitment to advancing organ-on-chip technologies that redefine preclinical research standards

The meeting represents a milestone for Italy’s stem cell community, strengthening scientific networks and fostering dialogue on innovation, translational research, and the ethical and technological frontiers of regenerative medicine.